ERA 2025大会新证：耐赋康®靶向“四重打击”机制 全面夯实IgA肾病首选对因治疗地位

Core Insights - The recent ERA 2025 conference showcased nine new studies on the drug Nefukang® (Budesonide Enteric Capsules), confirming its significant role in reducing pathogenic factors related to IgA nephropathy, particularly in the context of the "four-hit" theory of disease mechanism [1][4] - Nefukang® is the first and only approved drug for targeted treatment of IgA nephropathy in China, the US, and Europe, and has been included in the latest clinical management guidelines, emphasizing early and comprehensive treatment strategies [1][2] Group 1: Clinical Findings - Nefukang® has been shown to significantly lower Gd-IgA1 levels in the blood, impacting the first, second, and third hits of the "four-hit" theory, ultimately reducing kidney function deterioration by 50% [3] - The drug's mechanism involves specific modulation of gut mucosal immunity, which reduces the production of Gd-IgA1, thereby blocking the pathological pathways associated with IgA nephropathy [3][4] Group 2: Patient Impact - In China, over 5 million patients suffer from IgA nephropathy, with more than 100,000 new cases diagnosed annually, highlighting the urgent need for effective treatments [2] - Early treatment with Nefukang® is associated with more significant kidney function protection and disease progression delay, reinforcing the importance of timely intervention in managing IgA nephropathy [5] Group 3: Research Validation - Recent studies indicate that changes in Gd-IgA1 and polymeric IgA levels within the first two months of treatment correlate significantly with reductions in proteinuria, suggesting these markers could guide treatment efficacy [4] - The findings from the ERA 2025 conference provide robust clinical evidence supporting Nefukang® as a leading choice for targeted therapy in IgA nephropathy, potentially transforming treatment paradigms [5]